Fourpath Capital Management’s Merck MRK Stock Holding History

Fourpath Capital Management’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	18,997 +577	+3%	+$67.5K	0.32%	64
2026 Q1	$2.22M	Buy	18,420 +1,400	+8%	+$162K	0.32%	59
2025 Q4	$1.79M	Buy	17,020 +2,399	+16%	+$225K	0.25%	72
2025 Q3	$1.23M	Sell	14,621 -50	-0.3%	-$4.12K	0.17%	88
2025 Q2	$1.16M	Hold	14,671	–	–	0.18%	85
2025 Q1	$1.32M	Buy	14,671 +30	+0.2%	+$2.8K	0.23%	80
2024 Q4	$1.46M	Sell	14,641 -101	-0.7%	-$10.4K	0.27%	77
2024 Q3	$1.67M	Buy	14,742 +12,781	+652%	+$1.52M	0.31%	70
2024 Q2	$243K	Sell	1,961 -46	-2%	-$5.92K	0.18%	111
2024 Q1	$265K	Sell	2,007 -4	-0.2%	-$493	0.18%	105
2023 Q4	$219K	Sell	2,011 -7	-0.3%	-$727	0.15%	119
2023 Q3	$208K	Sell	2,018 -152	-7%	-$16.4K	0.16%	110
2023 Q2	$250K	Sell	2,170 -32	-1%	-$3.63K	0.3%	81
2023 Q1	$234K	Sell	2,202 -4,494	-67%	-$485K	0.16%	114
2022 Q4	$743K	Sell	6,696 -3,344	-33%	-$342K	0.54%	44
2022 Q3	$865K	Sell	10,040 -3,213	-24%	-$287K	0.59%	42
2022 Q2	$1.21M	Sell	13,253 -1,919	-13%	-$170K	0.75%	26
2022 Q1	$1.25M	Buy	15,172 +223	+1%	+$17.6K	0.49%	38
2021 Q4	$1.15M	Buy	+14,949	New	+$1.19M	0.44%	40

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fourpath Capital Management's MRK Position: Q2 2026 in Review

Fourpath Capital Management increased its Merck (MRK) stake by 3.1% in Q2 2026, buying an estimated $67.5K and bringing the position to 18,997 shares worth $2.44M. The position accounts for 0.32% of the portfolio, ranked #64.

Fourpath Capital Management first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. 3,832 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Fourpath Capital Management held 18,997 shares of Merck worth $2.44M as of Q2 2026.
Fourpath Capital Management bought 577 Merck shares in Q2 2026, an estimated $67.5K.
Merck made up 0.32% of Fourpath Capital Management's portfolio in Q2 2026, its #64 holding.
Fourpath Capital Management first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
3,832 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fourpath Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.